spacer
home > directory > BACHEM
PHARMACEUTICAL INDUSTRY DIRECTORY

BACHEM

BACHEM
***BACHEM. PIONEERING PARTNER FOR PEPTIDES*** Bachem is the leading independent supplier of peptidic active pharmaceutical ingredients (APIs) for the human and veterinary pharmaceutical market. Since its foundation in 1971, Bachem's concepts and technologies pioneered the industrial peptide manufacturing. Our pioneering mindset drives us to continue developing innovations and offering all integrated services needed to bring our partners breakthroughs to market. ***RESEACH: Bachem offers the world¡¦s largest collection of amino acid derivatives, linkers and reagents for peptide synthesis. In addition, solid phase supports for different synthesis strategies are available. Other key research products are bioactive peptides, enzyme substrates and inhibitors as well as organic molecules. New products are continuously added to meet new demands for innovative and high quality research chemicals. ***PRECLINICAL DEVELOPMENT: Our custom-made peptide service supports lead finding and optimization during preclinical development. Close collaboration with Bachem experts allows further refining of target compounds and consequent project advancement. A strong partnership is key to come up with pioneering concepts and molecules to bring into clinical development. ***CLINICAL DEVELOPMENT: Our partners can trust in our support and guidance from early development and selection of the lead compound, throughout all clinical phases and final drug approval. Each production step is scrutinized in order to guarantee manufacturing reproducibility and scale-up possibilities. Process validation and control is the result of the intense partnership between Bachem and our customers. ***PEPTIDE DRUGS: As a leading peptide Contract Manufacturing Organization, we guarantee the reliable supply of the drug substance by coordinating our activities closely with our partners. Bachem is currently involved in more than 150 cGMP development projects targeting new chemical entities (NCEs) and offers a range of more than 30 generic drug substances. We have the capacity to produce peptide APIs from gram scale up to annual quantities of hundreds of kilograms and small molecules APIs from gram scale up to annual quantities of tens of tons. The FDA and local authorities regularly inspect our GMP manufacturing facilities, located in Switzerland and the United States. In addition to close to 50 years of experience in the manufacture of drug substance, Bachem also has a strong regulatory background. We are well prepared to fully support our customers with the required regulatory documentation such as drug master files (DMFs). For complex development projects, we support our customers with dedicated project teams comprising of our experts from R&D, production, quality control, quality assurance and regulatory affairs. A team of experienced Business Development Managers and Generics Managers look forward to working with our customers for their future requirements. Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the Bachem group has a global reach. Bachem shows total commitment to quality, innovation and partnership.
phone +41 58 595 2021
email sales.ch@bachem.com
web www.bachem.com
email Hauptstrasse 144, 4416 Bubendorf
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement